Skip to main content
. Author manuscript; available in PMC: 2017 Jun 7.
Published in final edited form as: Stroke. 2016 Dec 27;48(2):379–387. doi: 10.1161/STROKEAHA.116.014735

Figure 2.

Figure 2

Scatter plot showing the joint distribution of the difference in lifetime cost and quality-adjusted life-expectancy between intravenous tissue-type plasminogen activator (IV tPA) alone and stent retriever thrombectomy according to bootstrap simulation (1000 replicates). The large solid dot indicates the base case value of Δ costs = $23 203 and Δ quality-adjusted life years (QALYs) = 1.743. The solid, diagonal line indicates the incremental cost-effectiveness ratio threshold of $50 000 per QALY gained.